Established theory of radiation-induced decay is not generalizable to Bolton-Hunter labeled peptides.
Peptide hormones radiolabeled with 125I are widely used for the pharmacological characterization of cognate receptors. As a prerequisite for calculating ligand affinities from competition binding assays, and for estimating receptor densities from such studies, it is necessary to know the concentration of bioactive radioligand that is used in respective experiments. It has been demonstrated previously that radioiodinated peptides undergo decay catastrophe, i.e. disintegration of the radioactive label leads to the concomitant destruction of the carrier peptide. Here, we demonstrate that decay catastrophe does not apply to two peptide hormones that are iodinated by Bolton-Hunter conjugation: cholecystokinin octapeptide and glucagon-like peptide 2. The function of aged samples of these radioligands at corresponding recombinantly expressed receptors was assessed by measuring ligand-induced inositol phosphate production or generation of cyclic AMP, respectively. Both of the tested compounds, although predicted by decay catastrophe to contain little or subthreshold remaining bioactivity, stimulated an unexpectedly high level of receptor-mediated second messenger signaling. Quantitative comparison of observed functions with those of corresponding unlabeled peptides suggested that the bioactivity of each radioligand had been largely conserved despite the radioactive decay of the iodine label. Consistent with an apparent absence of decay catastrophe, we noted that the specific radioactivity, when determined immediately following peptide iodination, was close to the theoretical maximum but exponentially decreased over time. These findings raise the possibility that attachment of a Bolton-Hunter conjugate may shield labeled peptides from radiation-induced damage, a scenario that should be considered when performing radioligand binding experiments.
Molecular Pharmacology Research Center, Molecular Cardiology Research Institute, Tufts-New England Medical Center, Box 7703, 750 Washington Street, Boston, MA 02111, USA.
Amanda C
AC
Doran
Yieh-Ping
YP
Wan
Alan S
AS
Kopin
Martin
M
Beinborn
D000818:Animals; D019556:COS Cells; D002766:Cholecystokinin / Q000737:chemistry / Q000494:pharmacology; D053767:Glucagon-Like Peptide 2; D004763:Glucagon-Like Peptides; D036361:Peptide Hormones / Q000737:chemistry / Q000494:pharmacology; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology; D011851:Radioactivity; D011869:Radioligand Assay; D019275:Radiopharmaceuticals / Q000737:chemistry / Q000494:pharmacology*
D053767:Glucagon-Like Peptide 2; D036361:Peptide Hormones; D010455:Peptides; D019275:Radiopharmaceuticals; D004763:Glucagon-Like Peptides; D002766:Cholecystokinin